Building Trust with Society
Building trust with society is a key pillar of the Novartis corporate strategy and is critical to delivering on our purpose of reimagining medicine to improve and extend people’s lives. It defines our approach to managing our key environmental, social and governance (ESG) topics and risks: being part of the solution on pricing and access, addressing global health challenges, being a responsible citizen, and holding ourselves to high ethical standards. Our ESG efforts are fully integrated across the company and are key to driving long-term value for our stakeholders.
We believe a focus on our material ESG topics, coupled with our inspired, curious and unbossed culture will drive better performance. ESG topics form a core component of how the Novartis Executive Committee and the Board of Directors evaluate long-term performance of the company. We are committed to reporting transparently on these topics through our Annual Reporting Suite, which includes the Novartis in Society Integrated Report, as well as our other Publications.
We apply our expertise and full organizational capability to address major, unresolved global health challenges.
Ethics, Risk and Compliance
We recognize society’s expectations of our industry and of Novartis, and that we must go beyond just doing what is legal in order to meet legitimate expectations of society.
We understand the link between the health of our planet and the health of our patients. Our ambition is to be a catalyst for positive change and a leader in environmental sustainability.
Diversity & Inclusion
We embrace and champion diversity and inclusion which fuels innovation, drives engagement, and attracts talent.
We aim to conduct business responsibly wherever we operate with a focus on building a strong ethical foundation, respect for human rights, patient health and safety, diversity and inclusion and the safety and well-being of our employees. We have clear commitments on many other social topics including the living wage, product quality and use of animals in research.
Staying one step ahead of the malaria parasite
Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.
Our corporate governance framework supports sustainable financial performance and long-term value creation and is aligned with our values and behaviors. In a rapidly changing business environment, we apply effective risk management to build resilience. We continue taking important steps to integrate our ESG agenda into the core of our business, enhancing executive accountability and measuring our performance against transparent targets. Members of the Executive Committee and other senior leaders have ESG targets in their annual objectives.
Transparent reporting has been a central part of our commitment for many years and we continue to make progress in this area.
We aim to enhance transparency and meet the needs and expectations of our stakeholders by offering access to key data on important areas of our business: payments to healthcare professionals, patient group funding, political contributions and clinical trial results.
Positions on key topics
As part of our ongoing commitment to transparency, we state our position on key issues affecting our business and of specific interest to our stakeholders.
Awards & Recognition
Novartis is honored to receive numerous awards for progress in research and development, our working environment, and our ESG activities.
ESG Rating Performance
Our performance against environmental, social and governance criteria is reflected in a variety of third-party ratings.